脾气好
发表于 2025-3-21 18:09:24
书目名称Small Molecules in Oncology影响因子(影响力)<br> http://figure.impactfactor.cn/if/?ISSN=BK0868499<br><br> <br><br>书目名称Small Molecules in Oncology影响因子(影响力)学科排名<br> http://figure.impactfactor.cn/ifr/?ISSN=BK0868499<br><br> <br><br>书目名称Small Molecules in Oncology网络公开度<br> http://figure.impactfactor.cn/at/?ISSN=BK0868499<br><br> <br><br>书目名称Small Molecules in Oncology网络公开度学科排名<br> http://figure.impactfactor.cn/atr/?ISSN=BK0868499<br><br> <br><br>书目名称Small Molecules in Oncology被引频次<br> http://figure.impactfactor.cn/tc/?ISSN=BK0868499<br><br> <br><br>书目名称Small Molecules in Oncology被引频次学科排名<br> http://figure.impactfactor.cn/tcr/?ISSN=BK0868499<br><br> <br><br>书目名称Small Molecules in Oncology年度引用<br> http://figure.impactfactor.cn/ii/?ISSN=BK0868499<br><br> <br><br>书目名称Small Molecules in Oncology年度引用学科排名<br> http://figure.impactfactor.cn/iir/?ISSN=BK0868499<br><br> <br><br>书目名称Small Molecules in Oncology读者反馈<br> http://figure.impactfactor.cn/5y/?ISSN=BK0868499<br><br> <br><br>书目名称Small Molecules in Oncology读者反馈学科排名<br> http://figure.impactfactor.cn/5yr/?ISSN=BK0868499<br><br> <br><br>
Prophylaxis
发表于 2025-3-21 21:06:32
http://reply.papertrans.cn/87/8685/868499/868499_2.png
浅滩
发表于 2025-3-22 00:33:01
http://reply.papertrans.cn/87/8685/868499/868499_3.png
高兴去去
发表于 2025-3-22 06:24:42
http://reply.papertrans.cn/87/8685/868499/868499_4.png
Pulmonary-Veins
发表于 2025-3-22 09:49:23
Regorafenib,tatic gastrointestinal stromal tumors (GIST) after progression on standard treatments and is also an FDA approved indication. Currently, regorafenib is examined in several clinical trials (mostly phase II) in different tumor entities, including renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and soft tissue sarcoma (STS).
Overstate
发表于 2025-3-22 14:38:26
http://reply.papertrans.cn/87/8685/868499/868499_6.png
Inelasticity
发表于 2025-3-22 20:08:18
http://reply.papertrans.cn/87/8685/868499/868499_7.png
Outshine
发表于 2025-3-23 00:59:34
http://reply.papertrans.cn/87/8685/868499/868499_8.png
Limited
发表于 2025-3-23 01:57:55
http://reply.papertrans.cn/87/8685/868499/868499_9.png
敲竹杠
发表于 2025-3-23 09:32:40
Ruxolitinib,olitinib through CYP3A4 needs to be considered particularly if co-administered with potent CYP3A4 inhibitors. Several further JAK inhibitors are currently studied in myelofibrosis or other immuno-inflammatory diseases.